roxifiban has been researched along with aspirin in 4 studies
| Studies (roxifiban) | Trials (roxifiban) | Recent Studies (post-2010) (roxifiban) | Studies (aspirin) | Trials (aspirin) | Recent Studies (post-2010) (aspirin) |
|---|---|---|---|---|---|
| 40 | 7 | 1 | 48,947 | 6,817 | 13,778 |
| Protein | Taxonomy | roxifiban (IC50) | aspirin (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.35 | |
| Integrin beta-3 | Homo sapiens (human) | 5 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.8252 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 1.375 | |
| Integrin alpha-IIb | Homo sapiens (human) | 5 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.271 | |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | 2.4 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 2.15 | |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 0.3 | |
| 4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | 2.4 | |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.35 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.4081 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cain, VA; Ebling, W; Fossler, MJ; Kornhauser, DM; Ma, S; Mondick, JT; Pieniaszek, HJ; Sy, SK | 1 |
| Barbera, FA; Dorsam, RT; Feuerstein, GZ; Friedman, SM; Gibbs, S; Lauver, A; Savion, N; Varon, D; Wang, H; Wang, X | 1 |
| Gurbel, PA; Malinin, AI; O'connor, CM; Serebruany, VL | 1 |
| Bozarth, JM; Feuerstein, GZ; Mousa, SA; Seiffert, D | 1 |
3 trial(s) available for roxifiban and aspirin
| Article | Year |
|---|---|
Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Amidines; Amino Acids; Area Under Curve; Aspirin; Bleeding Time; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Hydrolysis; Isoxazoles; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prodrugs; Time Factors | 2002 |
Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
Topics: Amidines; Aspirin; Coronary Disease; Coronary Thrombosis; Double-Blind Method; Female; Flow Cytometry; Humans; Isoxazoles; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Statistics, Nonparametric; Thrombolytic Therapy | 2003 |
Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans.
Topics: Amidines; Aspirin; Blood Coagulation; Calcium Chloride; Cross-Over Studies; Fibrin; Humans; Isoxazoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Reference Values; Thrombelastography | 2005 |
1 other study(ies) available for roxifiban and aspirin
| Article | Year |
|---|---|
Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
Topics: Abciximab; Alanine; Amidines; Analysis of Variance; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cell Aggregation; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Isoxazoles; Peptides; Platelet Activation; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Rheology; Shear Strength; Temperature; Tirofiban; Tyrosine | 2002 |